Only two of the clinical trials analyzed in the study provided weight data, which showed no difference in weight loss between those with and without PAM variants, but the data is too limited to be conclusive, Gloyn said
To understand where GLP1 is headed and what it means for manufacturers and retailers, we spoke with Leigh ODonnell, GLP1 expert and sponsor of Kantars Global GLP1 study, about the drivers behind its growth, how consumer behavior is changing, and why this shift is only just beginning
Who May Be a Better Candidate for Each Medication There is no single medication that works best for everyone
This is a research blend of two distinct and mechanistically complementary growth hormone secretagogues, supplied together to enable dual-pathway GH axis research in a single formulation
Liver: metabolic functions